Skip to Content

Cellular Biomedicine Group, Inc.

Merger

  • Date:
  • 8/12/2020
  • Company Name:
  • Cellular Biomedicine Group, Inc.
  • Stock Symbol:
  • CBMG
  • Company Name - Buyer:
  • CEO Bizuo Liu
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 8/12/2020

Case Finder

Locate any case using the tools below.

NEW YORK, August 12, 2020 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by a consortium led by Cellular Biomedicine’s CEO Bizuo Liu (“the Consortium”).

On August 12, 2020, Cellular Biomedicine announced that it had signed an agreement to be acquired by the Consortium. Pursuant to the merger agreement, Cellular Biomedicine’s stockholders will receive $19.75 in cash for each share of Cellular Biomedicine common stock owned.

Bragar Eagel & Squire is concerned that Cellular Biomedicine’s board of directors oversaw an unfair process and ultimately agreed to an inadequate deal price. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Cellular Biomedicine’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Cellular Biomedicine Group. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: